Disease Control

In order to produce disease-free swine, their organs, and tissue, the breeding stock used by Midwest Research Swine are vaccinated for the following organisms:
Porcine Parvovirus, Leptospira ssp., Erysipelothrixs, Circovirus Type 2

Prior to farrowing (birth), the sows are further vaccinated against microorganisms.

Production sows are monitored by Midwest Research Swine and the University of Minnesota, Veterinary Diagnostic Laboratory for the continuing presence of serological response to these vaccines. It has been shown that piglets produced by such sows will have high antibody tiers to these organisms derived antepartum from maternal serum and postpartum maternal colostrums. These antibodies are principal of the lgC class. The presence of such antibodies is taken as presumptive evidence that the herd and consequently unimmunized piglets do not harbor significant infections with these organisms.

The entire herd (breeding stock and finishing pigs) is also evaluated annually for antibodies to Pseudorabies and Brucella. State and federal regulations do not permit vaccination for these diseases in pigs intended for breeding stock or which are intended to be shipped across state lines. Antibody responses in such animals are expected to be negative.

The herd is also examined for ectoparasites and ascarids, both of which are important inhibitors of weight-gain in economic animals. No evidence of ectoparasites was found during the most recent herd health check. Since ascarids are present to some degree in most swine herds, control rather than elimination is the current practice. Resident animals (breeding sows) are periodically treated to reduce the risk of the appearance of resistant organisms.

Managing disease within our herd’s assists in providing animals used for medical research of the highest quality. The kind of quality that exceeds the national SPF requirements and meets the requirements of our herd.